CARS1 and neoplasm: CARs are recombinant transmembrane receptors composed of an extracellular binding domain of a monoclonal antibody for tumor‐associated antigen recognition, a hinge domain, and an intracellular signaling domain of a TCR molecule for initiating signal transduction that leads to T‐cell activation (Figure 2).[1] Similar to the treatment strategies employing monoclonal antibodies, T‐cells expressing CARs are highly targeted.